Kazunobu Kato

发表

The contribution of glycoprotein VI to stable platelet adhesion and thrombus formation illustrated by targeted gene deletion.

T. Kanaji, S. Russell, J. Ware, 2003, Blood.

Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma.

K. Savage, D. Neuberg, G. Pinkus, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes.

P. Bierman, I. Flinn, C. Flowers, 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

A prototypic platelet septin and its participation in secretion

P. Nurden, J. Ware, W. Trimble, 2002, Proceedings of the National Academy of Sciences of the United States of America.

Checkmate 205 Update with Minimum 12-Month Follow up: A Phase 2 Study of Nivolumab in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma

K. Savage, M. Shipp, A. Santoro, 2016 .

Convulxin binds to native, human glycoprotein Ib alpha.

T. Kanaji, J. Ware, T. Kunicki, 2003, The Journal of biological chemistry.

Genetic deletion of mouse platelet glycoprotein Ibβ produces a Bernard-Soulier phenotype with increased α-granule size

P. Nurden, S. Fiering, S. Russell, 2004 .

Genetic deletion of mouse platelet glycoprotein Ibbeta produces a Bernard-Soulier phenotype with increased alpha-granule size.

P. Nurden, S. Fiering, S. Russell, 2004, Blood.

Safety and efficacy of targeted-dose busulfan and bortezomib as a conditioning regimen for patients with relapsed multiple myeloma undergoing a second autologous blood progenitor cell transplantation.

G. Tricot, D. Reece, D. White, 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Additional Recognition Sites in the C-Terminal Heparin-Binding Domain of Fibronectin Promote Adhesion of PMA-Treated U937 Cells

H. Mohri, Y. Hashimoto, T. Okubo, 1998, Peptides.

Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation.

J. Dipersio, F. Appelbaum, M. Pasquini, 2013, Blood.

Genetic deletion of mouse platelet glycoprotein Ibproduces

P. Nurden, S. Fiering, S. Russell, 2004 .

- Soulier phenotype with increased produces a β Genetic deletion of mouse platelet glycoprotein Ib

P. Nurden, S. Russell, J. Ware, 2004 .

irradiation in hematopoietic cell transplantation Prospective cohort study comparing intravenous busulfan to total body

J. Dipersio, F. Appelbaum, M. Pasquini, 2013 .

Nitration of tyrosine residues 368 and 345 in the beta-subunit elicits FoF1-ATPase activity loss.

C. Giulivi, Kazunobu Kato, Y. Fujisawa, 2009, The Biochemical journal.

Critical overview of mitochondrial nitric-oxide synthase.

C. Giulivi, Kazunobu Kato, 2006, Frontiers in bioscience : a journal and virtual library.

Nitric oxide regulation of mitochondrial oxygen consumption I: cellular physiology.

C. Giulivi, Cecilia Giulivi, Kazunobu Kato, 2006, American journal of physiology. Cell physiology.

Nivolumab for classical Hodgkin lymphoma after autologous stem-cell transplantation and brentuximab vedotin failure: a prospective phase 2 multi-cohort study

K. Savage, M. Shipp, A. Ligon, 2016, The Lancet. Oncology.

Nivolumab for classical Hodgkin lymphoma after autologous stem-cell transplantation and brentuximab vedotin failure: a prospective phase 2 multi-cohort study

K. Savage, M. Shipp, A. Ligon, 2016, The Lancet. Oncology.

Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study.

M. Shipp, A. Ligon, S. Ansell, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of nitrative/nitrosative stress in mitochondria: Unraveling targets for malaria chemotherapy

C. Giulivi, S. Luckhart, Kazunobu Kato, 2007 .

Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma.

R. Advani, J. Vose, A. LaCasce, 2018, Blood.

Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial

K. Savage, M. Shipp, A. Santoro, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dosing algorithm revisit for busulfan following IV infusion

E. Rock, Yanlin Wang, Xiaofeng Wang, 2015, Cancer Chemotherapy and Pharmacology.

An open-label, single-arm phase 2 trial of valemetostat for relapsed or refractory adult T-cell leukemia/lymphoma

A. Utsunomiya, K. Izutsu, K. Tobinai, 2022, Blood.

A Global Phase 2 Study of Valemetostat Tosylate (Valemetostat) in Patients with Relapsed or Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL), Including R/R Adult T-Cell Leukemia/Lymphoma (ATL) - Valentine-PTCL01

S. Horwitz, P. Porcu, K. Izutsu, 2021, Blood.

Convulxin Binds to Native, Human Glycoprotein Ibα*

T. Kanaji, J. Ware, T. Kunicki, 2003, Journal of Biological Chemistry.

Pharmacokinetic-Directed Dose Adjustment Is Essential for Intravenous Busulfan Exposure Optimization: Findings From a Multi-Center Phase II Study of Autologous Hematopoietic Stem Cell Transplantation for Lymphoma in North America

P. Bierman, I. Flinn, T. Shea, 2013 .

A Phase 1 Dose Escalation Study of Milademetan in Combination with 5-Azacitidine (AZA) in Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

M. Andreeff, C. Dinardo, R. Olin, 2019, Blood.

Preliminary Results from a Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma

R. Advani, J. Vose, A. LaCasce, 2016 .

Improved Survival with Intravenous Busulfan (IV BU) Compared to Total Body Irradiation (TBI)-Based Myeloablative Conditioning Regimens: A CIBMTR Prospective Study

M. Pasquini, Xiaochun Zhu, P. McCarthy, 2013 .

Checkmate 205: Nivolumab (nivo) in classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT) and brentuximab vedotin (BV)--A phase 2 study.

K. Savage, M. Shipp, A. Santoro, 2016 .

Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) after Treatment with Nivolumab for Relapsed/Refractory Hodgkin Lymphoma

M. Millenson, A. Santoro, P. Zinzani, 2016 .

Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial

K. Savage, M. Shipp, A. Santoro, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation.

J. Dipersio, F. Appelbaum, M. Pasquini, 2013, Blood.

Effect of Co-Mutations and FLT3-ITD Variant Allele Frequency (VAF) on Response to Quizartinib or Salvage Chemotherapy (SC) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

A. Krämer, N. Russell, G. Martinelli, 2019, Blood.